Edition: Global  
One News Page
“Probably the fastest-access news portal in the world”
> >

Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South Korea

Business Wire Friday, 13 January 2017
Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South KoreaSAN DIEGO--(BUSINESS WIRE)--Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced its randomized, controlled Phase 2/3 clinical trial, called Toca 5, is now enrolling patients in South Korea. The trial is ongoing in the United States, Canada and Israel. The study compares a cancer-selective virus, Toca 511 (vocimagene amiretrorepvec), in combination with Toca FC (extended-release 5-fluorocytosine), to standard of care in patients with first or second recurrence
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 

Recent related news

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial
DIDCOT, England--(BUSINESS WIRE)--Karus announces that first patients have been dosed with its histone deacetylase 6 (HDAC6) inhibitor, KA2507, in a PhI clinical...
Business Wire - Press ReleasesAlso reported by •GlobeNewswireProactive InvestorsFinanzNachrichten.de

Formula Pharmaceuticals Announces Initiation of the First Clinical Trial for Allogeneic CIK-CAR Cancer Immunotherapy

Formula Pharmaceuticals, Inc. ("Formula") announced today the opening of the first clinical trial for allogeneic Cytokine Induced Killer (C.I.K.) cell-based...
FinanzNachrichten.de - MarketsAlso reported by •MarketwiredProactive InvestorsBusiness Wire

GeneOne Life Science Receives Approval for Phase I/IIa MERS-CoV Vaccine Trial in Korea

GeneOne Life Science Receives Approval of IND by the Korean Ministry of Food and Drug Safety (KMFDS) of MERS-CoV Plasmid DNA vaccine, GLS-5300, for a Phase I/IIa...
PRWeb - Press ReleasesAlso reported by •GlobeNewswire

Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
STRASBOURG, France--(BUSINESS WIRE)--$TNG #Avelumab--Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops viral-based...
Business Wire - Press ReleasesAlso reported by •GlobeNewswire

FDA Grants “Fast Track” Status to Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

FDA Grants “Fast Track” Status to Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/sul for Treatment of Familial Adenomatous Polyposis
TUCSON, Ariz.--(BUSINESS WIRE)--Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and...
Business Wire - Press Releases

Global Cancer Photodynamic Therapy Market & Cancer Photosensitisers Clinical Trial Outlook 2017-2023

DUBLIN, September 18, 2017 /PRNewswire/ -- The "Global Cancer Photodynamic Therapy Market & Cancer Photosensitisers Clinical Trial Outlook 2023" report has been...
FinanzNachrichten.de - MarketsAlso reported by •Business Wire

You Might Like


Other recent news in Press Releases

IBA SA : IBA and Elekta enter an MOU regarding a comprehensive partnership including joint SOFTWARE development and sales to advance proton therapy treatmentsStatement by Richard J. Gilfillan, M.D., Chief Executive Officer, Trinity Health, Regarding the Graham-Cassidy Health Care Measure
TORONTO-Based Startup Curate Mobile Releases New Mobile-First Programmatic Platform

Twitter

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+